

UROMITEXANE 400MG INJ

CLASS: Antidote; Uroprotectant

INDICATIONS: Preventative agent to reduce the incidence of ifosfamide-induced hemorrhagic cystitis

AVAILABLE DOSAGE FROM THE HOSPITAL:

UROMITEXANE 400MG INJ

DOSAGE:**Note:** Details concerning dosing in combination regimens should also be consulted. Mesna dosing schedule should be repeated each day ifosfamide is received. If ifosfamide dose is adjusted, the mesna dose should also be modified to maintain the mesna-to-ifosfamide ratio.

-Prevention of ifosfamide-induced hemorrhagic cystitis:

I.V.:

-Short infusion standard-dose ifosfamide (<2.5 g/m²/day): Mesna dose is equal to 60% of the ifosfamide dose given in 3 divided doses (0, 4, and 8 hours after the start of ifosfamide)

-Continuous infusion standard-dose ifosfamide (<2.5 g/m²/day): ASCO guidelines: Mesna dose (as an I.V. bolus) is equal to 20% of the ifosfamide dose, followed by a continuous infusion of mesna at 40% of the ifosfamide dose, continue mesna infusion for 12-24 hours after completion of ifosfamide infusion (Hensley, 2008)

-High-dose ifosfamide (>2.5 g/m²/day): ASCO guidelines: Evidence for use is inadequate; more frequent and prolonged mesna administration regimens may be required.

-I.V. followed by oral (for ifosfamide doses ≤2 g/m²/day): Mesna dose is equal to 100% of the ifosfamide dose, given as 20% of the ifosfamide dose I.V. at hour 0, followed by 40% of the ifosfamide dose given orally 2- and 6 hours after start of ifosfamide

Geriatric

Refer to adult dosing.

Renal Impairment

No dosage adjustment provided in manufacturer's labeling (has not been studied).

Hepatic Impairment

No dosage adjustment provided in manufacturer's labeling (has not been studied).

COMMON SIDE EFFECT:

Mesna alone (frequency not defined):

Cardiovascular: Flushing

Central nervous system: Dizziness, fever, headache, hyperesthesia, somnolence

Dermatologic: Rash

Gastrointestinal: Anorexia, constipation, diarrhea, flatulence, nausea, taste alteration/bad taste (with oral administration), vomiting

Local: Injection site reactions

Neuromuscular: Arthralgia, back pain, rigors

Ocular: Conjunctivitis

Respiratory: Cough, pharyngitis, rhinitis

Miscellaneous: Flu-like syndrome

Mesna alone or in combination: Postmarketing and/or case reports: Allergic reaction, anaphylactic reaction, hypersensitivity, hyper-/hypotension, injection site erythema, injection site pain, limb pain, malaise, myalgia, platelets decreased, ST-segment increased, tachycardia, tachypnea, transaminases increased

PREGNANCY RISK FACTORS: B